Advances in Immunotherapy: Bridging Monoclonal Antibodies and CAR-T Cell Therapies

Kishor Pant^1*Mark Charles Glassy^2*

• ¹University of Minnesota Twin Cities The Hormel Institute, Austin, United States
• ²University of California San Diego, La Jolla, United States

Chemotherapy, radiation therapy, and surgical intervention have been the primary modalities for cancer treatment in the past few decades [1]. Although these therapies often show short-term effectiveness, they exhibit many significant drawbacks, including toxicity, a lack of specificity, and the emergence of drug resistance. The scientific community is now exploring alternative ways that could provide more specific, persistent results with reduced undesirable consequences [2].Immunotherapy is an innovative approach that has attracted significant attention and has emerged as a potent instrument in the fight against cancer [3]. The basic principle of immunotherapy is simple but effective: using the human body immune system to identify, target, and eliminate cancer and proliferating cells. This technique has the potential for sustained disease management by utilizing the immune system's inherent ability to differentiate between healthy and aberrant cells and to adapt its response over time [3].Chimeric antigen receptor (CAR)-T cell therapy has transformed targeted immunotherapy, facilitating the treatment of both haematologic and solid tumours, in addition to non-oncologic disorders [4]. This innovative therapy originated from years of progressive developments in cell-based therapeutics and continues to advance to address significant challenges. The progress in immunotherapy is highlighted in this research topic, Current Trends in Immunotherapy: From Monoclonal Antibodies to CAR-T Cells. It addresses progress from innovative cellular therapies like CAR-T cells to treatments based on monoclonal antibodies. The included articles illustrate how the future of immune-based treatments is being affected by developments in genetics, bioengineering, and molecular biology (Figure 1).A variety of investigations focus on the interactions between immune cells and cancer cells, providing new insights into how tumors evade immune identification and strategies to counteract these evasion mechanisms [5]. Others concentrate on the development of immune checkpoint inhibitors, which have revolutionised the management of malignancies such as renal cell carcinoma, non-small cell lung cancer, and melanoma. This chapter also addresses the increasing prominence of personalised vaccinations, oncolytic viruses, and bispecific antibodies [6].CAR-T cell therapy, wherein a patient's T cells are genetically modified to identify and target cancer, is among the most interesting and complex subjects addressed [7]. Initially developed for haematological malignancies, research is currently broadening its use to solid tumours, addressing challenges such as antigen heterogeneity and inhibition by the tumour microenvironment [7]. This collection of essays emphasises the progress and promise of immunotherapy as a robust and adaptable cancer treatment approach. They highlight ongoing challenges that must be addressed to fully actualise the potential of immunotherapy, including immunerelated toxicities, variability in patient responses, and the substantial expense of certain medicines.Immunotherapy is now considered a validated treatment mode. It is now strongly recognized as the fourth pillar of cancer treatment, alongside radiation, chemotherapy, and surgery [8]. Immunotherapy is expected to have increasing significance in personalized and precision oncology as research advances our understanding of the immune system and its interactions with cancer [8]. This research topic serves as a resource for researchers, physicians, and students, encapsulating a specific point in the growth of the field.